D. Jarrossay

Human neutralizing antibodies to cold linear epitopes and to subdomain 1 of SARS-CoV-2

The paper identifies broadly cross-reactive neutralizing antibodies against SARS-CoV-2 variants using coldspot-guided antibody discovery.

Anti-chemokine antibodies after SARS-CoV-2 infection correlate with favorable disease course

The paper finds that anti-chemokine antibodies after SARS-CoV-2 infection correlate with favorable disease outcomes and predict absence of long COVID symptoms.

ACE2 engagement exposes the fusion peptide to pan-coronavirus neutralizing antibodies

The paper identifies monoclonal antibodies that neutralize multiple coronaviruses by targeting the fusion peptide, which becomes exposed upon ACE2 engagement.

Clonal dissection of immunodominance and cross-reactivity of the CD4+ T cell response to SARS-CoV-2

The paper identifies immunodominant and cross-reactive CD4+ T cell epitopes in SARS-CoV-2, showing their recognition in 93% of patients and potential for vaccine design.

Human T-bet governs innate and innate-like adaptive IFN-γ immunity against mycobacteria

This study identifies T-bet deficiency as a cause of mycobacterial disease by impairing IFN-γ production in innate and innate-like adaptive lymphocytes.